Valuation: SourcingLink.net, Inc.

Market Cap 2.71M 2.34M 2.18M 2.01M 3.79M 258M 3.84M 25.74M 10.08M 128M 10.16M 9.94M 426M P/E 2003 *
-
P/E 2004 -
Enterprise Value 2.71M 2.34M 2.18M 2.01M 3.79M 258M 3.84M 25.74M 10.08M 128M 10.16M 9.94M 426M EV / Sales 2003
-
EV / Sales 2004 -
Free-Float
100%
Yield 2003 *
-
Yield 2004 -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+9.50% - - 2.71M
-0.53%-3.95%+50.70%+153.56% 1,024B
+0.21%-2.68%+53.20%+51.79% 618B
-2.51%-3.25%+28.54%+68.94% 443B
+0.06%-0.42%+37.53%+30.67% 349B
-0.69%-0.30%+13.76%+12.83% 264B
-7.37%-4.40%-0.74%-44.28% 209B
-0.64%+2.43%+29.74%+65.93% 208B
-0.82%+0.70%+15.05%+72.05% 162B
+0.40%+1.92%+6.47%-29.77% 143B
Average -1.19%-1.21%+26.03%+42.41% 379.88B
Weighted average by Cap. -1.00%-2.02%+36.14%+71.90%

Financials

2003 2004
Net sales 3.28M 2.84M 2.65M 2.43M 4.6M 313M 4.65M 31.19M 12.22M 156M 12.32M 12.05M 516M 1.18M 1.02M 952K 875K 1.65M 113M 1.68M 11.23M 4.4M 56.07M 4.44M 4.34M 186M
Net income -1.52M -1.32M -1.23M -1.13M -2.13M -145M -2.16M -14.45M -5.66M -72.17M -5.71M -5.58M -239M -1.56M -1.35M -1.26M -1.16M -2.19M -149M -2.22M -14.88M -5.83M -74.3M -5.88M -5.75M -246M
Net Debt -1.35M -1.17M -1.09M -997K -1.89M -128M -1.91M -12.8M -5.01M -63.9M -5.05M -4.94M -212M 17K 14.72K 13.71K 12.6K 23.82K 1.62M 24.12K 162K 63.34K 807K 63.84K 62.44K 2.67M
Logo SourcingLink.net, Inc.
Oncology Pharma, Inc. is an oncology company. The Company is focused on licensing, developing, manufacturing and commercializing therapeutics. The Company’s research, development, and commercialization of therapeutic drugs and medical devices designed for the treatment of many types of cancers. The Company offers a portfolio, such as Nanosmart Pharmaceuticals Inc. (Nanosmart Pharmaceuticals). The Company’s NanoSmart platform technology is a human-derived, antinuclear antibody (ANA) that targets areas of necrosis present in solid tumors. Its anti-cancer drugs in combination with medications, for treating a variety of cancers, such as breast, ovarian, lung, bladder, Kaposi's sarcoma, lymphoma and acute lymphocytic leukemia is doxorubicin. Its portfolio also includes Connect2Med, Sybleu, Inc. and Regen.
Employees
-